Thrombosis Drugs Market Set to Record Exponential Growth by 2026 End

Transparency Market Research (TMR) titled “Thrombosis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the new report, the global thrombosis drugs market was valued at approximately US$ 20,012 Mn in 2017. It is projected to expand at a CAGR of more than 9.5% from 2018 to 2026.

The report suggests that the rise in geriatric population, which is more susceptible to thrombosis events, globally, is likely to boost the demand for thrombosis drugs during the forecast period. North America and Europe are likely to dominate the global thrombosis drugs market due to increase in awareness and rise in focus of key players on the development of new drugs in the market in these regions. Increasing penetration and rising prevalence of thrombosis events in emerging markets such as Japan, Hong Kong, and Taiwan are likely to boost the thrombosis drugs market in Asia Pacific at a CAGR of 9.0% from 2018 to 2026.

Obtain Report Details @ https://www.transparencymarketresearch.com/thrombosis-drugs-market.html

Expansion of the Generic Drugs Industry to Hamper the Market

The generic drugs industry has witnessed significant expansion in the last few years. Branded drugs of molecule such as heparin consistently lose market share due to the availability and continuous launch of generic version of the drugs. For example, recently, in January 2018, Aurobindo Pharma launched fondaparinux sodium injection, a generic version of Arixtra brand, which is utilized to prevent deep vein thrombosis, after its patent expired.

Low Molecular Weight Heparin to Lose Market Share

The report offers detailed segmentation of global thrombosis drugs market based on drug class, indication, and distribution channel. Based on drug class, the factor Xa inhibitor drugs segment is estimated to account for a large share of the global market by the end of the forecast period. This is due to the increase in utilization of factor Xa inhibitor drugs for their advantages such as no drug monitoring is required after intake.

Moreover, several studies have proved that factor Xa inhibitor drugs are effective in both deep vein thrombosis and pulmonary embolism and help reduce the rate of hospitalization after usage. The low molecular weight heparin segment is anticipated to lose market share during the forecast period, and is expected to decline from 14.7% held in 2017 to reach 5.9% by 2026. Patent expiry, availability of generic drugs, and increased preference toward oral formulation of drugs from injectable dose are factors that are likely to hamper this segment.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=46293

Pulmonary Embolism: Top Indication of Thrombosis Drugs

In terms of indication, the pulmonary embolism segment is projected to hold for a dominant share of the global thrombosis drugs market by the end of the forecast period. The segment is likely to expand at a CAGR more than 10.0% from 2018 to 2026. Most companies are focused on developing low-cost drugs to serve the large pulmonary embolism patients pool across the globe; therefore, the pulmonary embolism segment is likely to account for a dominant share of the market.

For example, the U.K-based pharmaceutical company, AstraZeneca, is developing a drug candidate called Brilliant Thales for the indication of cardiovascular events. The atrial fibrillation segment accounted for more than 27.0% share of the global thrombosis drugs market, in terms of value, in 2017. It is anticipated to expand at a substantial pace during the forecast period. The segment is likely to gain market share marginally to reach 27.8% by 2026.

The Market in North America to Expand at a Considerable Pace and Create Incremental Opportunity

In terms of value, North America held a major share of the global market in 2017. This is due to the high health care expenditure and rise in awareness about the advantages of new oral anticoagulant drugs formulation in the U.S. Furthermore, several players such as Johnson & Johnson and Exithera Pharmaceutical have increased investment in research & development to develop advanced drugs to treat thrombosis. Thus, the presence of these players is projected to propel the thrombosis drugs market in North America at a rapid pace during the forecast period. Increase in incidence of age-related chronic conditions such as cancer and neurological illnesses increases thrombosis events in Asia Pacific.

Moreover, improving economic conditions, rise in spending power, and better access to health care service fuels the market in Asia Pacific. Economic growth in countries such as Brazil is increasing research & development activities and expenditure on treatment in Latin America. These factors are likely to propel the thrombosis drugs market in Latin America. It is expected to expand at a CAGR of 9.0% from 2018 to 2026.

Enquiry for Discount on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=46293

Bayer AG, Aspen Pharmacare Holdings Limited, and Boehringer Ingelheim GmbH to Dominate the Market

The report also provides profiles of leading players operating in the global thrombosis drugs market. These include GlaxoSmithKline plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, and Pfizer, Inc. Expansion of product portfolio through developing new products or by acquisition and licensing agreement to develop products is a key strategy adopted by several key players. For instance, in 2015, Isis Pharmaceuticals, Inc., entered into an exclusive license agreement with Bayer HealthCare to develop and commercialize ISIS-FXIRx for the prevention of thrombosis. Other key players are also adopting such strategies.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.